Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.
DEM BioPharma is an immuno-oncology company focused on developing innovative therapies aimed at eradicating cancer by targeting the innate immune system. The company has created a platform that specializes in the next generation of macrophage immunotherapies, which work by activating macrophages and immune phagocytes to effectively eliminate tumors. By researching and harnessing these immune responses, DEM BioPharma aims to provide healthcare researchers with advanced treatments that specifically target signals on both cancer cells and macrophages, offering new hope in the fight against cancer.
Developer of genetic medicines intended to treat cancer and other immune diseases. The company's medicines provide elegant cutting-edge in vivo gene delivery technology that uses potent lentiviral vector-like particles to precisely deliver in vivo genetic cargo to the desired target tissue, enabling physicians to get a pipeline of drugs for solid tumors and hematologic cancers and other immune diseases.
Free Market Health operates a care-driven marketplace aimed at simplifying the specialty medication fulfillment process. The company's referral and reimbursement ecosystem facilitates competition among providers for authorized patient referrals that align with their specific care models. By streamlining critical aspects of referral distribution and reimbursement, Free Market Health enhances accountability and clarifies value drivers in patient care. This approach not only benefits providers by creating a level playing field but also ensures that patients receive timely access to essential medications from competent and motivated healthcare professionals. Overall, Free Market Health's platform fosters a coordinated environment that addresses the complexities of healthcare delivery.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.
Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, focused on developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in oncology by targeting specific pathways associated with acquired resistance. Tyra Biosciences employs its proprietary precision medicine platform, SNÅP, to facilitate rapid drug design through molecular snapshots, enabling the prediction of genetic alterations that may lead to resistance against existing therapies. The company's lead product candidate, TYRA 300, is an FGFR3 selective inhibitor, primarily aimed at treating patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through innovative approaches, Tyra Biosciences seeks to create next-generation precision medicines that significantly improve treatment outcomes for cancer patients.
DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services based in Denver, Colorado. Founded in 2013, the company offers a wide range of services including acute injury and illness evaluations, laceration repair, splinting of injured extremities, treatment for nosebleeds, placement of Foley and G-tubes, medication administration, laboratory testing, and coordination with primary care physicians and home health agencies. By delivering care in the comfort of patients' homes, DispatchHealth aims to reduce unnecessary emergency room visits and hospitalizations, improve clinical outcomes, and lower overall healthcare costs. The organization focuses on creating an integrated and convenient healthcare solution that enhances the capabilities of patients' care teams and ensures high-quality care.
PatientsLikeMe, Inc. operates a healthcare data-sharing platform that allows patients to share their symptoms, treatments, and health experiences with a broad audience, including caregivers, researchers, and pharmaceutical companies. This platform aims to enhance the understanding of various health conditions, such as cancer, mental health issues, and chronic diseases, ultimately contributing to the development of new treatments. With over 600,000 members, PatientsLikeMe serves as a trusted source for real-world disease information and has published more than 100 research studies, demonstrating its commitment to integrating patient voices into research and public policy. The company collaborates with major pharmaceutical firms and government organizations to advance health management and outcomes. Founded in 2004 and based in Cambridge, Massachusetts, PatientsLikeMe is a subsidiary of United Healthcare Services, Inc.
Transcarent is a consumer digital health company, uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions. We believe that having the right information, tools, and incentives in the decision-making process can be positively transformative in the way we all experience healthcare.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services based in Denver, Colorado. Founded in 2013, the company offers a wide range of services including acute injury and illness evaluations, laceration repair, splinting of injured extremities, treatment for nosebleeds, placement of Foley and G-tubes, medication administration, laboratory testing, and coordination with primary care physicians and home health agencies. By delivering care in the comfort of patients' homes, DispatchHealth aims to reduce unnecessary emergency room visits and hospitalizations, improve clinical outcomes, and lower overall healthcare costs. The organization focuses on creating an integrated and convenient healthcare solution that enhances the capabilities of patients' care teams and ensures high-quality care.
Lassen Therapeutics focuses on developing antibody biotherapeutics aimed at treating fibrosis, rare diseases, and cancer. The company's lead candidate, LASN01, is a monoclonal antibody that specifically targets the IL-11 receptor alpha, which is a key mediator in fibrosis and tumor growth. By inhibiting IL-11, Lassen Therapeutics aims to offer a more effective treatment alternative compared to traditional approaches that target other factors like TGF-β and CTGF. The company leverages advanced antibody technologies to create innovative therapeutics that address the complexities of the tumor microenvironment and the role of cytokines in various diseases, ultimately striving to enhance patient outcomes for those affected by serious health conditions.
Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, focused on developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in oncology by targeting specific pathways associated with acquired resistance. Tyra Biosciences employs its proprietary precision medicine platform, SNÅP, to facilitate rapid drug design through molecular snapshots, enabling the prediction of genetic alterations that may lead to resistance against existing therapies. The company's lead product candidate, TYRA 300, is an FGFR3 selective inhibitor, primarily aimed at treating patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through innovative approaches, Tyra Biosciences seeks to create next-generation precision medicines that significantly improve treatment outcomes for cancer patients.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits.
It was founded in 2018 and headquartered in Seattle, Washington.
DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services based in Denver, Colorado. Founded in 2013, the company offers a wide range of services including acute injury and illness evaluations, laceration repair, splinting of injured extremities, treatment for nosebleeds, placement of Foley and G-tubes, medication administration, laboratory testing, and coordination with primary care physicians and home health agencies. By delivering care in the comfort of patients' homes, DispatchHealth aims to reduce unnecessary emergency room visits and hospitalizations, improve clinical outcomes, and lower overall healthcare costs. The organization focuses on creating an integrated and convenient healthcare solution that enhances the capabilities of patients' care teams and ensures high-quality care.
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.
CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.
Everside Health is a direct primary care provider offering convenient on-site, near-site, and virtual care for its members. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician, and the benefit provider, all while reducing the total cost of care.
Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.
DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services based in Denver, Colorado. Founded in 2013, the company offers a wide range of services including acute injury and illness evaluations, laceration repair, splinting of injured extremities, treatment for nosebleeds, placement of Foley and G-tubes, medication administration, laboratory testing, and coordination with primary care physicians and home health agencies. By delivering care in the comfort of patients' homes, DispatchHealth aims to reduce unnecessary emergency room visits and hospitalizations, improve clinical outcomes, and lower overall healthcare costs. The organization focuses on creating an integrated and convenient healthcare solution that enhances the capabilities of patients' care teams and ensures high-quality care.
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
GenePeeks, Inc. is a genetic information company focused on helping families mitigate the risk of heritable diseases. Established in 2009 and based in New York, the company has developed a proprietary software platform that utilizes Next-Generation sequencing data to simulate the genetic recombination that occurs during human reproduction. By digitally weaving together the DNA of prospective parents, GenePeeks' technology generates analytic targets that represent tens of thousands of "virtual genomes," offering insights into the potential genetic profile of future children. This approach enables the identification of disease risks that are not detectable through existing pre-conception screening methods, providing valuable genetic insight for healthcare professionals and prospective parents.
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.
Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.
Private Equity Round in 2014
St. George's University, founded in 1976 in Saint George's, Grenada, offers a diverse range of undergraduate and graduate programs in medicine, veterinary medicine, arts and sciences, and public health. Originally established as an independent School of Medicine, it has evolved into a prominent center for international education, attracting students and faculty from 140 countries. The university boasts a multicultural campus equipped with advanced facilities and has produced over 14,000 graduates, including physicians, veterinarians, and public health professionals who work globally. St. George's University is accredited by various governing authorities and maintains affiliations with educational institutions across the United States, the United Kingdom, Canada, Australia, and Ireland. It significantly contributes to the Grenadian economy, injecting over US $100 million annually through salaries, housing, and community initiatives. The university is deeply involved in community outreach, supporting local charities and health programs while providing scholarships exceeding US $70 million since 2005 to Caribbean students pursuing various fields. Its research efforts have enhanced health and economic conditions in Grenada and the Caribbean, reaffirming its commitment to improving healthcare systems regionally and globally.
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California.
Lumena Pharmaceuticals focuses on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target a transporter in the intestine, minimizing systemic absorption and reducing the risk of toxicities. Lumena's lead candidate, LUM001, has been thoroughly evaluated in over 12 clinical studies involving more than 1,400 subjects, positioning it for rapid advancement in clinical trials for both pediatric and adult patients with various forms of cholestatic liver disease. In addition to its primary objective of creating novel treatments for rare liver conditions, Lumena's innovative therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which represent a significant and growing health concern among both children and adults.
ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for cancer treatment. It specializes in designing proprietary product candidates that aim to stimulate the patient's immune system to combat tumor cells effectively. By harnessing the body's natural defenses, Kite Pharma seeks to create novel strategies for managing various cancer types, ultimately aiming to improve outcomes for cancer patients. The company's commitment to advancing cell therapy positions it as a significant player in the biopharmaceutical landscape dedicated to addressing the challenges of cancer treatment.
Lumena Pharmaceuticals focuses on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target a transporter in the intestine, minimizing systemic absorption and reducing the risk of toxicities. Lumena's lead candidate, LUM001, has been thoroughly evaluated in over 12 clinical studies involving more than 1,400 subjects, positioning it for rapid advancement in clinical trials for both pediatric and adult patients with various forms of cholestatic liver disease. In addition to its primary objective of creating novel treatments for rare liver conditions, Lumena's innovative therapeutic approach also holds potential for addressing metabolic diseases affecting the liver, which represent a significant and growing health concern among both children and adults.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.
Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.
Carbylan Therapeutics, founded in 2004 and headquartered in Palo Alto, California, is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing proprietary combination therapies. The company's primary focus is on addressing pain associated with osteoarthritis of the knee, utilizing innovative approaches that include polysaccharides, biopolymers, and related pharmaceutical products. Carbylan Therapeutics aims to deliver effective therapies to meet significant unmet clinical needs in large and growing markets.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company is advancing several product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials, and achromatopsia, currently in Phase I/II trials. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal disease. The company has also initiated a preclinical program in otology and three preclinical programs targeting central nervous system disorders such as frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. Collaborations with various organizations, including Synpromics Limited and the University of Florida, support its research efforts. Founded in 1999 and based in Alachua, Florida, AGTC employs advanced gene therapy techniques, aiming to replace defective genes with functional ones, thus improving patient outcomes with long-lasting treatments.
ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Bioventus LLC develops and/or markets orthobiologic solutions for bone fusion and osteoarthritis. Its active healing therapies product line supports accelerated and more complete healing of bone fractures, and treats the chronic pain associated with osteoarthritis; and bone healing solutions work to enhance the body’s natural healing process. The company also provides injection therapies that treat osteoarthritic joints relieve pain and help bring mobility back to the patient; and surgical orthobiologics. Its products are available through a network of distributors. The company was incorporated in 2011 and is based in Durham, North Carolina. Bioventus LLC operates as a subsidiary of Bioventus Inc.
SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop that lowers elevated intraocular pressure in glaucoma patients, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for treating open-angle glaucoma and ocular hypertension. Additionally, Aerie is advancing its clinical-stage product AVX-012 for dry eye and developing sustained-release implants AR-1105 and AR-13503 for retinal diseases. Established in 2005, Aerie is headquartered in Durham, North Carolina, with research facilities in Research Triangle Park. The company has also formed a collaborative research and development agreement with DSM.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.
PneumRx, Inc. is a medical device company that specializes in developing minimally invasive treatments for patients with emphysema. Founded in 2004 and headquartered in Mountain View, California, the company is known for its RePneu Lung Volume Reduction Coil, an investigational device aimed at improving the quality of life for individuals suffering from this chronic respiratory condition. PneumRx focuses on addressing unmet medical needs in pulmonary medicine through innovative solutions.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Pathwork Diagnostics, located in Redwood City, California, specializes in molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. The test leverages genomic information from a tumor to enhance diagnostic precision and can be applied to various specimen types, including frozen tissue and formalin-fixed, paraffin-embedded samples. Through its advanced diagnostic solutions, Pathwork Diagnostics aims to improve clinical outcomes in cancer care.
Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
Abionyx Pharma is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular and metabolic diseases. The company specializes in high-density lipoprotein (HDL) therapies, including HDL mimetics aimed at reversing atherosclerotic plaque in high-risk patients. Its lead candidate, CER-001, is an engineered complex designed to replicate the properties of pre-beta HDL and is currently in Phase II clinical trials for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Additionally, CER-209, which is in Phase I trials, targets metabolic diseases affecting the liver, as well as conditions like atherosclerosis and non-alcoholic steato-hepatitis. Founded in 2005 and based in Labege, France, Abionyx Pharma emerged from Cerenis Therapeutics, adopting its current name in 2019. The company's portfolio also includes a drug delivery platform targeting HDL for potential applications in oncology, particularly in immuno-oncology and chemotherapy.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Stamford, Connecticut, specializing in the development of innovative therapies for pain and pruritus. The company's lead product candidate, CR845 (difelikefalin), is being tested in Phase III clinical trials for chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Additionally, the company is advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is also being evaluated for its effects on pruritus related to chronic liver disease and atopic dermatitis. Cara is also working on CR845/difelikefalin injection, which has completed Phase II/III trials for acute post-operative pain. The company has established licensing agreements with Maruishi Pharmaceutical Co., Ltd. in Japan and Chong Kun Dang Pharmaceutical Corporation in South Korea for the development and commercialization of CR845/difelikefalin. With a focus on leveraging proprietary drug-screening technology, Cara aims to build a pipeline of first-in-class therapeutic candidates targeting pain and inflammation.
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California.
FoldRx Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing disease-modifying drug therapies for conditions related to protein misfolding and amyloidosis. The company’s pipeline includes advanced clinical programs targeting genetic neurological and cardiovascular disorders, specifically transthyretin-associated amyloidoses that affect both polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in early-stage discovery efforts aimed at addressing diseases such as Parkinson's and cystic fibrosis. Established in 2003 and headquartered in Cambridge, Massachusetts, the company aims to provide effective treatments for the accumulation of misfolded proteins caused by genetic mutations and deficiencies in cellular quality control mechanisms.
Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.
TransMedics is a medical technology company focused on improving organ transplant therapy for patients with end-stage organ failure. Headquartered in Andover, Massachusetts, it has developed the Organ Care System (OCS), a portable organ perfusion and monitoring device that mimics near-physiologic conditions for donor organs outside the human body. This system includes specialized devices for different organs, such as OCS LUNG, which maintains lungs in a viable state for assessment and optimization, OCS Heart, designed to preserve hearts in a metabolically active state, and OCS Liver, currently under clinical trials. By addressing the limitations of traditional cold storage methods, TransMedics aims to enhance organ preservation and increase the availability of organs for transplantation, thereby improving outcomes for patients in need. Founded in 1998, the company is at the forefront of innovation in organ transplant technology.
Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California.
Coapt Systems, Inc. specializes in the design, development, and manufacturing of bio-absorbable implants intended for soft tissue fixation in facial cosmetic surgery. Its product offerings include various fixation devices such as the ENDOTINE Forehead 3.0 and ENDOTINE Midface ST 4.5, which are employed in procedures like forehead lifts, brow lifts, and midface suspensions. The company also provides surgical instruments and tools, including insertion kits and manual drills, to facilitate the use of its implants. Coapt Systems aims to support surgeons in achieving effective and secure tissue fixation during surgical procedures, enhancing outcomes for patients undergoing cosmetic interventions.
Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening.
Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.
Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
Aegis Semiconductor
Series E in 2009
Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.
7TM Pharma is a biotech company established in 2000 and located in Lyngby, Hovedstaden. The company specializes in discovering and developing therapeutic drugs aimed at addressing significant unmet medical needs in various conditions, particularly diabetes, obesity, gastrointestinal, metabolic, asthma, and vascular diseases. Among its key offerings are TM38837, a small molecule CB1 receptor antagonist, and TM30339, a selective NPY Y4 agonist designed to treat gastrointestinal disorders and short bowel syndrome. Additionally, the company has developed a CRTH2 antagonist, an oral medication targeting inflammatory and respiratory diseases. Through its innovative approaches, 7TM Pharma strives to provide effective treatments for patients suffering from these conditions.
Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.
Mako Surgical is a medical device company that specializes in advanced robotic arm solutions and orthopedic implants for minimally invasive knee and hip procedures. The company is known for its flagship product, MAKOplasty, which provides a restorative surgical option for orthopedic surgeons to address early to mid-stage osteoarthritic conditions in patients. The core technology includes a robotic arm interactive orthopedic system that features a tactile robotic arm and an integrated bone cutting instrument, along with a visualization component that assists surgeons with pre-operative and intra-operative guidance. This innovative approach facilitates tissue-sparing bone removal and ensures precise implant insertion and alignment. Founded in 2004 and headquartered in Florida, Mako Surgical has gained recognition for its rapid growth and commitment to customer service in the medical technology sector.
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.
Xelerated Inc. is a fabless semiconductor company specializing in the development and design of computer network equipment. The company offers a range of products, including HX devices that deliver wirespeed performance suitable for carrier backbone platforms, access aggregation, and enterprise switching systems. Additionally, Xelerated produces Xelerator network processors and provides a Software Development Kit that supports the development, simulation, debugging, and testing of applications for these processors. The company also supplies Reference Design Kits for network processor development and a Precision Time Solution that aids in implementing Precision Time Protocol and Synchronous Ethernet. Xelerated’s solutions cater to various applications, such as data-aware transport platforms, switches and routers, metro Ethernet switches, and access equipment. Founded in 2000 and headquartered in Santa Clara, California, Xelerated has additional offices in Tel Aviv, Beijing, and Stockholm.
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.
Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.
SurgRx, Inc is a developer of laparoscopic vessel fusion tools for surgical hemostasis. The company develops tissue sealing and hemostasis systems for laparoscopic and open surgery. It also offers EnSeal, a tissue sealing and hemostasis system that allows surgeons to seal and transect vessels, pedicles, and tissue bundles to achieve surgical hemostasis. SurgRx, Inc is based in Redwood City, California.
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Sonexa Therapeutics, Inc., a pharmaceutical company, engages in the development of therapeutics drugs for the treatment of Alzheimer's disease and related disorders. It develops ST101, a small and orally active molecule compound that penetrates the blood-brain-barrier. The company was incorporated in 2007 and is based in San Diego, California.